Representational image
Bhubaneswar: The World Health Organization (WHO) has recommended two new drugs – Eli Lilly & Co.’s rheumatoid arthritis drug and GlaxoSmithKline Plc’s monoclonal antibody – for treating patients with COVID-19.
According to the WHO Guideline Development Group, Lilly’s Baricitinib drug is “strongly recommended” for patients with severe or critical disease in combination with corticosteroids. It is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis.
The recommendation is based on “moderate certainty evidence” that it improves survival and reduces the need for ventilation.
The experts have advised against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) in such cases.
The WHO has recommended the use of a monoclonal antibody, known as Sotrovimab, in non-severe cases. The drug should only be administered to patients at the highest risk of hospitalisation, such as the elderly, people with immunodeficiencies or chronic diseases such as diabetes.
Last year, the WHO had approved Regeneron Pharmaceuticals Inc’s monoclonal antibody to treat COVID patients.
Bhubaneswar: With cyclonic storm Fengal forming over southwest Bay of Bengal, the India Meteorological Department…
Bhubaneswar: Odisha made the state proud by emerging champions in the U-19 T20 National Cricket Championship…
Mumbai: The Enforcement Directorate (ED) on Friday conducted raids at 15 premises, including that of…
Bhubaneswar: Prime Minister Narendra Modi was felicitated by BJP leaders at the meeting venue near…
Bhubaneswar: Union Home Minister Amit Shah inaugurated the 59th DGs and IGs conference at Lok…
Bhubaneswar: Land commons in Odisha, forests, pastures, and uncultivated lands spanning over 5 million hectares,…
New Delhi: The Vishva Hindu Parishad (VHP) announced a two-day nationwide protest from Friday to…
Bhubaneswar: A cyclonic storm formed over southwest Bay of Bengal around 2.30 pm on Friday,…